20.500.12556/DiRROS-22659 Remission of chronic urticaria in patients treated with omalizumab Introduction: This study examined the remission probability and duration in chronic spontaneous urticaria (CSU) patients resistant to second-generation H1-antihistamines (sgAHs) undergoing omalizumab treatment. Methods: This is a retrospective observational study of 176 adult CSU patients exhibiting a significant pruritus component (≥ 8) of the weekly urticaria activity score (UAS7) despite four daily sgAH tablets and starting omalizumab treatment with 300 mg every 4 weeks. After excluding 13 nonresponders, we analyzed 163 omalizumab responders (mean age 51.8 years, 74.4% female). The intervals between applications were increased. Discontinuation was considered for patients that remained asymptomatic on a gradually reduced dosage (to 150 mg every 12 weeks) without sgAHs. Results: Omalizumab discontinuation was possible in 25.8% (42/163). The duration of omalizumab treatment before remission ranged from 7 to 6 months. Twenty-one patients (50.0%) maintained complete remission until the end of the observation period (September 2021) for 8 to 68 months. Of the relapsed patients, 71.4% (15/21) effectively controlled CSU with sgAHs. Six patients (28.6%; 6/21) required omalizumab reintroduction after 6 to 40 months of remission, responding favorably. Conclusions: The study shows that a quarter of severe CSU patients achieve long-term remission. In addition, sgAHs effectively manage symptoms in a majority of relapsed cases, and those requiring omalizumab reintroduction respond favorably. urticaria antihistamines omalizumab urticaria remission urticaria relapse koprivnica antihistaminiki omalizumab remisija koprivnice relaps koprivnice true false true Slovene Welding Society Acta dermatovenerologica Alpina, Panonica et Adriatica Angleški jezik Slovenski jezik Authors publishing in our journal retain copyright of their work under the Creative Commons Attribution License (CC BY 4.0). This license allows unrestricted use, distribution, and reproduction of the work in any medium, provided the original author(s) and copyright holder(s) are appropriately credited, and the original publication in the journal is properly cited, following established academic practices. Neznano 2025-06-16 10:08:40 2025-06-16 10:08:40 2025-10-24 03:51:53 0000-00-00 00:00:00 2024 0 0 Soavtorji: Mojca Bizjak, Julij Šelb, Mitja Košnik; str. 59-61 iss. 2 Vol. 33 Jun. 2024 0000-00-00 Zaloznikova Objavljeno apc 2024-01-09 2024-05-05 2024-06-03 616 1318-4458 10.15570/actaapa.2024.12 198342403 actaapa.2024.12.pdf actaapa.2024.12.pdf 1 FF225E2AD2412145FCAA6A92A630CC70 d3255a5f5b8d7db53bc0236c6f937999d95ff675dde6e52ff86dd6b7c6e9b561 58c909e1-4a78-11f0-bf0a-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=32836 RAZ_Cvenkel_Klara_2024.pdf RAZ_Cvenkel_Klara_2024.pdf 1 07A468AB1AD94B9887153B0368726A1D b9f644451e41cd4e6e709a322b197a9e86d0d28a6068036e6221dadc16186dfb 7aa679b6-4a79-11f0-bf0a-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=32837 Univerzitetna klinika za pljučne bolezni in alergijo Golnik 0 0 0